help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hohenhaus, E.
Right arrow Articles by Bartsch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hohenhaus, E.
Right arrow Articles by Bartsch, P.

Am. J. Respir. Crit. Care Med., Vol 150, No. 3, 09 1994, 857-860.

Nifedipine does not prevent acute mountain sickness

E Hohenhaus, F Niroomand, S Goerre, P Vock, O Oelz and P Bartsch
Department of Sports Medicine, University of Heidelberg, Germany.

Nifedipine has been shown effective for prevention and treatment of high altitude pulmonary edema (HAPE). Because acute mountain sickness (AMS) and HAPE may share common pathophysiologic mechanisms, we evaluate the prophylactic effect of nifedipine on the development of AMS in 27 mountaineers not susceptible to HAPE. They were randomly assigned to receive in a double-blind manner either nifedipine or placebo during rapid ascent to 4559 m and a subsequent three-day sojourn at this altitude. Nine of 14 subjects on nifedipine and eight of 13 subjects on placebo felt ill at high altitude. Pulmonary artery pressures (PAP) estimated by Doppler echocardiography were significantly lower with nifedipine, but arterial PO2, oxygen saturation, and alveolar-arterial oxygen pressure gradient were not significantly different between groups at high altitude. This study demonstrates that lowering PAP has no beneficial effect on gas exchange and symptoms of AMS in subjects not susceptible to HAPE. Therefore, nifedipine cannot be recommended for prevention of AMS, and its use in high altitude medicine should be limited to prevention and treatment of HAPE.


This article has been cited by other articles:


Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
L. M. Spooner, J. L. Olin, and R. J. Debellis
Pharmacotherapy of High-Altitude Illness
American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 129 - 141.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
M. Maggiorini, H.-P. Brunner-La Rocca, S. Peth, M. Fischler, T. Bohm, A. Bernheim, S. Kiencke, K. E. Bloch, C. Dehnert, R. Naeije, et al.
Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.
Ann Intern Med, October 3, 2006; 145(7): 497 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Erba, S. Anastasi, O. Senn, M. Maggiorini, and K.E. Bloch
Acute mountain sickness is related to nocturnal hypoxemia but not to hypoventilation
Eur. Respir. J., August 1, 2004; 24(2): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
L. Dumont, C. Mardirosoff, and M. R Tramèr
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review
BMJ, July 29, 2000; 321(7256): 267 - 272.
[Abstract] [Full Text]

Home page
 CirculationHome page
S. Goerre, M. Wenk, P. Bartsch, T. F. Luscher, F. Niroomand, E. Hohenhaus, O. Oelz, and W. H. Reinhart
Endothelin-1 in Pulmonary Hypertension Associated With High-Altitude Exposure
Circulation, January 15, 1995; 91(2): 359 - 364.
[Abstract] [Full Text]

Home page
 JWatch GeneralHome page
NIFEDIPINE FAILS TO PREVENT MOUNTAIN SICKNESS
Journal Watch (General), October 14, 1994; 1994(1014): 5 - 5.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1994 American Thoracic Society